INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

15th International Conference on Malignant Lymphoma

 

June 18-22, 2019 Lugano
Close
N. Poster
Poster title
Applicant name
Status
  136-P One-year real-life targeted next generation sequencing for lymphoma diagnosis: study of patients from the French Lymphoma Network in Rhne-Alpes Cme Bommier Received Received
  137-P MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS Alfredo Rivas-Delgado Received Received
  138-P Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study Vincent Camus Received Received
  139-P Analysis of Circulating Tumor DNA (ctDNA) in Cerebrospinal Fluid Detects the Presence of Central Nervous System (CNS) Involvement in B-Cell Lymphomas Sabela Bobillo Received Received
  140-P Molecular analyses and an innovative diagnostic algorithm in MYC-negative Burkitt-like lymphoma with 11q aberration: a single institution experience Grzegorz Rymkiewicz Received Received
  141-P High risk of adverse events after autologous stem-cell transplantation in lymphoma patients with DNA repair pathway mutations: A nation-wide cohort study Simon Husby Received Received
  144-P Personalized prediction in DLBCL enabled by functional mouse genomics Clemens A. Schmitt Received Received
  146-P Population-Based Outcomes in Large B-cell lymphoma by WHO Subtype: Findings from the UKs Haematological Malignancy Research Network Russell Patmore Received Received
  147-P Refinement of MUM1 expression threshold for Double Positive CD10 MUM1 Diffuse Large B Cell Lymphoma allows a better Cell of Origin Classification for GCB subtype Celine Bossard Received Received
  148-P Reduced BCL2 expression suggests alternative survival mechanisms in HIV() Diffuse Large B Cell Lymphoma (DLBCL) of Germinal Center Origin Alanna Maguire Received Received
  149-P Single cell level analysis of MYC/ BCL2/ BCL6 co-expression in Diffuse large B-cell lymphoma through multiplexed quantitative immunofluorescence Michelle Poon Received Received
  150-P Clinical significance of T-cell exhaustion in patients with diffuse large B-cell lymphoma Sirpa Leppa Received Received
  151-P The influence of tumor immune microenvironment and tumor immunity on the pathogenesis, treatment and prognosis of post-transplant lymphoproliferative disorders (PTLD) Saito Hideaki Received Received
  152-P JAK-STAT pathway and epigenetic regulators are critical players in BI-ALCL pathogenesis ? Camille Laurent Received Received
  153-P Chromosome 20 loss is characteristic for Breast-implant Associated Anaplastic Large Cell Lymphoma Bauke Ylstra Received Received
  154-P Whole Genome Sequencing Reveals Potential Therapeutic Strategy for MEITL Dachuan Huang Received Received
  155-P Whole-genome sequencing reveals immunotherapeutic options for Natural-killer/T cell lymphoma patients. Jing Quan Lim Received Received
  156-P KIR3DL2 Mutation may Define a High Rate of Response of AITL to Tipifarnib antonio gualberto Received Received
  158-P A PTCL gene signature capturing stromal and neoplastic data stratifies PTCL/NOS and AITL into different groups with variable survival probability Marta Rodriguez Received Received
  159-P Multicentric MFI30 study: standardization of CD30 expression by flow cytometry in Non-Hodgkin lymphoma. Lucile BASEGGIO Received Received
  160-P Survival continues to increase in chronic lymphocytic leukemia: a population-based analysis among 20,324 patients diagnosed in the Netherlands between 1989 and 2015 Lina van der Straten Received Received
  161-P Proteomics markers prognostic for outcome of chronic lymphocytic leukemia patients under treatment: results from the HOVON-109 study Lina van der Straten Received Received
  164-P Hypertension (HTN) in Patients (Pts) treated with Ibrutinib (Ibr) for Chronic Lymphocytic Leukemia (CLL) MARYAM SARRAF YAZDY Received Received
  165-P An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 or more prior therapies Ian Flinn Received Received
  166-P Effect of dose modifications on response to duvelisib in patients with relapsed/refractory CLL/SLL in the DUO trial Paolo Ghia Received Received
  167-P Patterns of duvelisib-induced lymphocytosis in patients with R/R CLL or SLL including those with high-risk factors treated in the DUO trial Jacqueline Barrientos Received Received
  168-P Brief co-administration of idelalisib may improve the long-term efficacy of frontline chemoimmunotherapy in chronic lymphocytic leukaemia: 3-year follow-up from the RIAltO trial Andrew Pettitt Received Received
  170-P Long term follow up of FoRT: A Phase 3 Multi-Center Prospective Randomized Trial of Radiation Therapy for Follicular and Marginal Zone Lymphoma Amy Kirkwood Received Received
  171-P Systemic therapy after Radiation Therapy in stage I-II follicular lymphoma: Final results of an International Randomized Trial TROG 99.03 Michael MacManus Received Received
  172-P Results of a Multicenter Phase2 Trial of Involved Field Radiotherapy Alone for Localized Non-Gastric Marginal Zone Lymphoma: TROG 05.02 Michael MacManus Received Received
  173-P Outcomes of 180 Patients with Indolent Lymphomas Treated with Very Low Dose (4 Gy) Radiation Therapy Alone Karen Chau Received Received
  175-P FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY Simone Ferrero Received Received
  176-P Rituximab alone (R) versus rituximab plus bendamustine (BR) for splenic (SMZL) and nodal marginal zone lymphoma (NMZL). Adam Olszewski Received Received
  180-P Outcomes after early transformation (tPOD24) vs. early follicular lymphoma progression (fPOD24) in follicular lymphoma treated with frontline immunochemotherapy Matthew Maurer Received Received
  182-P WhiMSICAL (Waldenstrms Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-derived Data Registry Mapping Treatment and Quality of Life. Ibrahim Tohidi-Esfahani Received Received
  184-P Clinico-biological characteristics and treatment outcomes for Agressive Mantle Cell Lymphoma patients included in clinical trials. A LYSA study. Mathieu Baldacini Received Received
  186-P Evolution of clonal hematopoiesis in mantle cell lymphoma patients before, during, and after induction chemotherapy and autologous stem cell transplantation Simon Husby Received Received
  188-P Early progression of mantle cell lymphoma depicts a high-risk disease with poor response to subsequent therapies and a dismal outcome Christian Winther Eskelund Received Received
  189-P The efficacy of ibrutinib in patients with relapsed mantle cell lymphoma after first line intensive chemo-immunotherapy and ASCT a retrospective study from the LWP-EBMT Claire Burney Received Received
  190-P IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA Chiara Rusconi Received Received
  192-P The Clinical Course of Diffuse Large B-cell Lymphoma (DLBCL) over Time: A Multistate Survival Analysis Using Meta-Data From 13 First-line Randomized Trials a&287;lar a&287;layan Received Received
  193-P Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): an individual patient-level analysis across international trial Norbert Schmitz Received Received
  194-P The Elderly Project by the Fondazione Italiana Linfomi: a Prospective Comprehensive Geriatric Assessment (CGA) of 1353 Elderly Patients with Diffuse Large B-Cell Lymphoma Michele Spina Received Received
  196-P Clinical Characteristics and Outcomes of Stage I Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab-Era Sabela Bobillo Received Received
  197-P Population-based study on different regimens of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma in the Netherlands supports the use of 6 cycles of R-CHOP21 Djamila Issa Received Received
  198-P PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL) Monica Balzarotti Received Received
  199-P SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL Emma Verner Received Received
  200-P Prospective multicenter registry for secondary CNS involvement in malignant lymphoma: an update with data from 181 patients Felicitas Lammer Received Received
  203-P Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Preliminary results of the R2-GDP-GOTEL Trial Luis de la Cruz Merino Received Received
  204-P MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before CD19 CAR T Therapy Brandon Imber Received Received
  205-P Highly Favorable Outcomes with Salvage RT Followed by ASCT in Relapsed & Refractory DLBCL Patients Refractory to Salvage Chemotherapy Joanna Yang Received Received
  206-P Post-transplant Lymphoproliferative Disorder in Patients with Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation Ayumi Fujimoto Received Received
  207-P Depth of remission following first line HP-eradication is an independent prognostic factor in gastric MALT lymphoma Markus Raderer Received Received
  208-P 90Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) The Zeno Study Marangon Miriam Received Received
  209-P Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including PCR-based clonality analysis Barbara Kiesewetter Received Received
  210-P Incidence and Treatment Outcomes of Patients with Transformed Marginal Zone Lymphoma Treated with RCHOP-Like Regimens Sridevi Rajeeve Received Received
  211-P Allogeneic hematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: Data from the Japan Society for Hematopoietic Cell Transplantation Eisei Kondo Received Received
  212-P PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) RADIOTHERAPY (RT) Theodoros Vassilakopoulos Received Received
  213-P Is it radiotherapy necessary for primary mediastinal B-cell lymphoma (PMBL) patients achieving PET negativity after immunochemotherapy? Marie Trnkova Received Received
  214-P PD-1 Inhibitor plus Chemotherapy in Relapsed/refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL) with Aggressive Bulky Disease Qian Mei Received Received
  215-P Temozolomide in relapse/refractory primary vitreo-retinal lymphoma (R/R PVRL): a simple, cheap, effective and well tolerated treatment. Result of the largest study on R/R PVRL, from the LOC network Sylvain Choquet Received Received
  216-P Clinical features, treatment and outcome of Neurolymphomatosis: Single Institution experienceTitle Mattia Novo Received Received
  217-P Bicentric pilot study on age-adapted high-dose chemotherapy and autologous stem cell transplant in newly diagnosed primary CNS lymphoma patients 65 years - MARiTA trial Elisabeth Schorb Received Received
  219-P PD-1 blockade in a French series of 13 relapsed / refractory NK/T-cell lymphoma patients Lucile Couronné Received Received
  220-P A prospective phase II study of pegaspargase-COEP plus radiotherapy in patients with newly diagnosed extra-nodal NK/T-cell lymphoma Shaoxuan Hu Received Received
  222-P CLINICAL OUTCOMES AND DIAGNOSIS-TO-TREATMENT INTERVAL IN PATIENTS WITH NK/T-CELL LYMPHOMA: 7-YEAR FOLLOW-UP OF THE NKEA STUDY Motoko Yamaguchi Received Received
  223-P Clinicopathological differences of nodal PTCL with Tfh phenotype from AITL and PTCL, NOS, and detection of prognostic marker of nodal PTCL with Tfh phenotype Takaharu Suzuki Received Received
  224-P EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP Kitsada Wudhikarn Received Received
  225-P Bone Marrow Involvement, but No Blood Involvement, Impairs Survival in Angioimmunoblastic T cell Lymphoma: An Ancillary Study of the REVAIL Trial Francois Lemonnier Received Received
  227-P Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results Matthew Lunning Received Received
  229-P Anaplastic Large Cell Lymphoma, ALK-Negative: analysis of 235 Cases collected by the T-Cell Project. monica civallero Received Received
  230-P Increased Risk of Second Primary Hematologic and Solid Malignancies in Patients with Mycosis Fungoides: Impact on Overall Survival in SEER Registry Aleksandr Lazaryan Received Received
  233-P CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS. Gregorio Barilà Received Received
  234-P Clinical characteristics and outcome of patients with Hodgkins lymphoma older than 60 years treated in Switzerland over the last 17 years Stefanie Aeppli Received Received
  236-P DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI Rita Mazza Received Received
  238-P PET-adapted nivolumab /- ICE as initial salvage therapy in relapsed/refractory Hodgkin lymphoma Alex Herrera Received Received
  239-P Transcriptional networks associated with treatment failure in advanced-stage Hodgkin lymphoma: data from the RATHL trial (CRUK/07/033) Sean Lim Received Received
  241-P First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of FIL ONLUS Stefoni Vittorio Received Received
  243-P CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES chiara de philippis Received Received
  244-P How to donor, stem cell source, and conditioning regimen for haploidentical transplants with post-transplant cyclophosphamide for lymphoma: a report of the EBMT LWP Ali Bazarbachi Received Received
  246-P REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM Catherine Thieblemont Received Received
  247-P Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001 Maria Wering Received Received
  249-P Safety and Efficacy of Axicabtagene Ciloleucel (axi-cel) in Older Patients: Results from The US Lymphoma CAR-T Consortium Dahlia Sano Received Received
  251-P Phase 1 Study of AntiCD19 CAR-T Cells with TNFa Transmembrane Domain and 41BB, CD3zeta Costimulatory Domains. Responses in Subjects with Rapidly Progressive Lymphoma Paolo Caimi Received Received
  252-P CD19/CD20-redirected bispecific CAR T cell treatment in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma Yao Wang Received Received
  256-P Clinical Implications of Cytopenias Beyond Day 30 after Axi-cel Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma Paolo Strati Received Received
  257-P Comprehensive report of anti-CD19 chimeric antigen receptor T-cells (CAR-T) associated Non Relapse Mortality (CART-NRM) from FAERS Kartik Anand Received Received
  258-P Safety of Allogeneic Hematopoietic Cell Transplant in Adults after CD19 Targeted Chimeric Antigen Receptor-modified T-cell (CAR-T) Therapy Mazyar Shadman Received Received
  259-P Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) Ahmed Sawas Received Received
  260-P Ipilimumab plus Lenalidomide for Treatment of Relapsed Disease after Allogeneic Stem Cell Transplantation (AlloSCT) in Patients (pts) with Lymphoid Malignancies Issa Khouri Received Received
  261-P Donor lymphocyte infusions induce durable responses in patients with follicular, mantle and T cell lymphomas relapsing after an alloSCT. An EBMT-LWP Study. Stephen Robinson Received Received
  267-P Reversal of immune tolerance and increased survival after XPO1 and BTK inhibition in mouse models of primary CNS lymphoma (PCNSL) Isabel Jiménez Received Received
  269-P The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHL emmanuel normant Received Received
  271-P Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in advanced B-cell malignancies. Shannon Matheny Received Received
  272-P Long-term outcome of patients with relapsed/refractory B-cell non- Hodgkin lymphoma treated with bispecific antibody blinatumomab in a phase I trial Vera Dufner Received Received
  273-P A first-in-human trial of the novel multi-action therapy tinostamustine (EDO-S101) in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) Gillian Wain Received Received
  277-P Safety and efficacy of venetoclax combined with rituximab, ifosfamide, carboplatin and etoposide (VICER) for treatment of relapsed DLBCL: Final results from the Phase 1 Trial Paolo Caimi Received Received
  278-P Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jean-Marie Michot Received Received
  279-P Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) and follicular lymphoma (FL) David Sermer Received Received
  280-P Safety and efficacy of atezolizumab, obinutuzumab and venetoclax combination for relapsed/refractory non-Hodgkin lymphomas: Results from the safety-run of a LYSA study Charles Herbaux Received Received
  281-P Phase 1B Study of ViPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy Christopher Melani Received Received
  285-P Title: Improvement of Rituximab administration by premedication with rupatadine, montelukast and their combination rouslan Kotchetkov Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30 Fri 8:30-15:00
13:58
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

15th International Conference on Malignant Lymphoma

 

June 18-22, 2019 Lugano
HELP LINE
Manage Orders
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 18/06/2019 TO 18/06/2021
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.15ICML.2019 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 16/06/2019
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster




PosterSessionOnline
Logo Draft
 
Logo Cert